Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1597605 | 0.98 | SIGMAR1 (0.68) | SIGMAR1MKNK1MKNK2HPGDCHRNB2 | |
| SCHEMBL7425708 | 0.92 | MKNK1 (0.72) | SIGMAR1MKNK1MKNK2HPGDRIPK1 | |
| Trifluoroacetic Acid SCHEMBL3961759 | 0.89 | SIGMAR1 (0.61) | SIGMAR1MKNK1MKNK2HPGDCHRNB2 | |
| Pyridine SCHEMBL28123146 | 0.88 | SIGMAR1 (0.81) | SIGMAR1MKNK1MKNK2HPGDTSHR | |
| SCHEMBL8358137 | 0.88 | SIGMAR1 (0.81) | SIGMAR1MKNK1MKNK2HPGDALDH1A1 | |
| SCHEMBL12893509 | 0.85 | MKNK1 (0.53) | SIGMAR1MKNK1MKNK2HPGDCHRNB2 | |
| Tert-Butyl Formate SCHEMBL28289050 | 0.84 | HPGD (0.55) | SIGMAR1MKNK1MKNK2HPGDCHRNB2 | |
| Hydrochloric Acid SCHEMBL1597604 | 0.84 | TSHR (0.64) | HPGDCYP3A4TP53TSHRSMN1; SMN2 | |
| SCHEMBL4229238 | 0.83 | GABRD (0.71) | CYP3A4TSHRCYP2C9CYP2C19HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL6199874 | 0.83 | L3MBTL1 (0.62) | SIGMAR1MKNK1MKNK2HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103992338-B | A kind of copper complex based on two pyridine piperazine part and Anderson type polyacid and synthetic method thereof and application | BOHAI UNIVERSITY (CN) | 2016-04-13 | — | — | CN | claimed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4574153-A2 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | University of Miami (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250188092-A1 | RIFAMYCIN ANALOGS | THE PENN STATE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | disclosed |
| US-20250145586-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | UNIVERSITY OF MIAMI | 2025-05-08 | — | — | US | disclosed |
| EP-3704103-B1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | UNIV MIAMI (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-111801322-B | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | 迈阿密大学 | 2024-03-15 | — | — | CN | disclosed |
| US-11926613-B2 | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | UNIVERSITY OF MIAMI (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117682988-A | Wangzaozi B derivative, and preparation method and application thereof | 宿州绿源中医药科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-0703908-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5461047-A | Analgesics and treats prostaglandin-E2 mediated diseases in animals | G. D. SEARLE & CO. (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1994029286-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5354747-A | Analgesics | G. D. SEARLE & CO. (US) | 1994-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | SIGMAR1 3026/4885MKNK1 1777/4885MKNK2 1955/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | SIGMAR1 938/4885MKNK1 1928/4885MKNK2 2358/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | SIGMAR1 3134/4885MKNK1 74/4885MKNK2 47/4885 |
| US-11926613-B2 | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | PNCK, PYGB, PMP22 | SIGMAR1 1713/4885MKNK1 114/4885MKNK2 126/4885 |
| US-20250188092-A1 | RIFAMYCIN ANALOGS | CYP3A4, CYP4B1, CYP2C9 | SIGMAR1 1001/4885MKNK1 2665/4885MKNK2 2463/4885 |
| US-20250145586-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | MAP3K20, MAP4K2, MAP4K1 | SIGMAR1 2242/4885MKNK1 68/4885MKNK2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.